Effects of Rapamycin on Age-Associated Vasculature Transcription Profiles
Rapamycin (Rapa), an mTOR1 inhibitor, is one of the few therapies shown to prolong lifespan. It also may mitigate the adverse effects of age on the vasculature. To explore the vascular transcription profiles of age-associated pathways in mice treated with Rapa, mice were 1? treated with varying dosing regimens of Rapa beginning at 20 months of age?. The mice were checked twice daily for health status and were euthanized at 22 months of age. The aortas of mice were collected, and RNA was extracted from the aortas. RNA was then tested to ensure the collected samples were of adequate quality for RNA-sequencing analysis. We expect that the mice experiencing prolonged lifespan in response to Rapa treatment will have differences in their transcription profiles compared to young and old mice which had not been treated with Rapa. This information may provide insight related to the effects of Rapa towards prolongation of lifespan and may direct future studies in humans.
Effects of Rapamycin on Age-Associated Vasculature Transcription Profiles Read More »



